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Evaluation of responses to vaccination of Angus cattle for four viruses that
contribute to bovine respiratory disease complex
Abstract
While vaccination is an effective measure in reducing the risk of bovine respiratory disease complex (BRDC)
in cattle, BRDC losses remain significant. Increasing the efficacy of vaccination depends on elucidating the
protective immune response to different antigens included in vaccines, determining the best timing for
vaccination and understanding the impact of the age of calf on vaccination. This study measured the serum
antibodies present in calves following vaccination against four viruses commonly associated with BRDC:
bovine viral diarrhea virus 1 and 2 (BVDV1 and BVDV2), bovine respiratory syncytial virus (BRSV), and
bovine herpesvirus (BHV1). Serum antibody titers were measured in more than 1600 calves at 3- week
intervals starting at time of first vaccination. This first vaccination occurred at weaning for approximately half
of the individuals, and three weeks before weaning for the other half. Dam age (years), time of weaning (initial
vaccination or booster vaccination), and age of calf within year-season (days within Year-Season) classification
all were found to have a significant effect on measured traits such as initial titer and overall response. Increased
initial titer was negatively correlated with each response trait (initial, booster, and overall response). Calves
that were weaned at initial vaccination had greater overall antibody response to BVDV1 and BVDV2
compared to calves weaned 3 weeks before initial vaccination. In contrast, calves given their initial vaccination
3 weeks before weaning had greater overall antibody response to BRSV and BHV1 compared to calves that
were vaccinated at weaning. Furthermore, the circulating antibody titer at which each virus needed to be
below for an individual calf to positively respond to vaccination was determined (log base-2 titer of 0.38 for
BVDV1, 1.5 for BVDV2, 3.88 for BRSV, 1.5 for BHV1). This information can be used to improve vaccination
protocols to allow for a greater response rate of individuals to vaccination and hopefully improved protection.
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ABSTRACT 
While vaccination is an effective measure in reducing the risk of bovine respiratory 
disease complex (BRDC) in cattle, BRDC losses remain significant. Increasing the efficacy of 
vaccination depends on elucidating the protective immune response to different antigens 
included in vaccines, determining the best timing for vaccination and understanding the impact 
of the age of calf on vaccination. This study measured the serum antibodies present in calves 
following vaccination against four viruses commonly associated with BRDC: bovine viral 
diarrhea virus 1 and 2 (BVDV1 and BVDV2), bovine respiratory syncytial virus (BRSV), and 
bovine herpesvirus (BHV1). Serum antibody titers were measured in more than 1600 calves at 3-
week intervals starting at time of first vaccination. This first vaccination occurred at weaning for 
approximately half of the individuals, and three weeks before weaning for the other half. Dam 
age (years), time of weaning (initial vaccination or booster vaccination), and age of calf within 
year-season (days within Year-Season) classification all were found to have a significant effect 
on measured traits such as initial titer and overall response. Increased initial titer was negatively 
correlated with each response trait (initial, booster, and overall response). Calves that were 
weaned at initial vaccination had greater overall antibody response to BVDV1 and BVDV2 
compared to calves weaned 3 weeks before initial vaccination. In contrast, calves given their 
initial vaccination 3 weeks before weaning had greater overall antibody response to BRSV and 
BHV1 compared to calves that were vaccinated at weaning. Furthermore, the circulating 
antibody titer at which each virus needed to be below for an individual calf to positively respond 
to vaccination was determined (log base-2 titer of 0.38 for BVDV1, 1.5 for BVDV2, 3.88 for 
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BRSV, 1.5 for BHV1). This information can be used to improve vaccination protocols to allow 
for a greater response rate of individuals to vaccination and hopefully improved protection. 
 
Key words: beef cattle; bovine respiratory disease complex; immune response; vaccination; 
weaning 
INTRODUCTION 
As one of the most costly diseases in the beef cattle industry, Bovine Respiratory Disease 
Complex (BRDC), results in an estimated loss of more than $750 million a year due to 
morbidity, mortality, reduced growth performance, and reduced carcass quality (Snowder et al., 
2007; Irsik, 2010; Van Eenennaam, 2012). Vaccines vary in efficacy (Theurer et al., 2015), 
resulting in reduced overall herd immunity when calves are grouped in feedlots. Maternally-
derived antibodies passively obtained via colostrum are vital for early calf health (Roth, 2008) 
and assist protection, but present barriers to vaccination. Calves may not mount a vaccination 
antibody response if maternal antibody levels are too high (Niewiesk, 2014), and if too low, 
calves may be at risk before vaccination induces protective immunity. As such, vaccination 
should occur at a time that calves can positively respond, but still remain protected by maternal 
antibodies. 
 Environmental stressors are often associated with an altered immune state (Salak-Johnson 
and McGlone, 2007; Wein et al., 2016). Weaning has been shown to lower the immune response 
in calves, and therefore may reduce the effectiveness of vaccination depending on its timing 
(Hulbert and Moisa, 2016). 
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 This study built upon previous work (Downey et al., 2013) with vaccination against 
Bovine Viral Diarrhea Virus type 2. By examining response to vaccination traits to four viruses 
associated with BRDC (Bovine Viral Diarrhea Virus type 1 [BVDV1], Bovine Viral Diarrhea 
Virus type 2 [BVDV2], Bovine Respiratory Syncytial Virus [BRSV], Bovine Herpesvirus 
[BHV1]), it was possible to identify environmental commonalities associated with immune 
response to vaccination. The objectives were to identify management and environmental factors 
that 1) that impact the level of BVDV1, BVDV2, BRSV, and BHV1 circulating maternal 
antibodies at initial vaccination, 2) influence the rate of BVDV1 and BVDV2 maternal antibody 
decay prior to initial vaccination, and 3) influence response to vaccination against BVDV1, 
BVDV2, BRSV, and BHV1 to improve vaccination practices. 
MATERIALS AND METHODS 
Animals 
 Purebred American Angus calves (n = 2,834) from the Iowa State University herd were 
utilized for this study. Not all individuals had recorded response to vaccination phenotype 
records for each of the 4 viral antigens due to samples being analyzed in batches according to 
contemporary group and differences in time between samples being analyzed for each antigen. 
Due to these time differences, only a subset of the total herd humber could be used when 
examining response to vaccination for a given virus. Phenotypic data (body weights, ages, 
infectious bovine keratoconjunctivitus classification score(Lepper et al., 1992), and weaning 
status) were collected on each animal when serum samples were taken. Calves were born in 
either of 2 seasons (spring or fall) across multiple years (2006 to 2012, 2014). The number of 
calves with recorded measurments was on average about 350 per year, with more individuals in 
the spring season compared to the fall season. The only exceptions to this were years 2012 and 
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2014, in which only spring born calves had measurements and the average number of calves was 
226 per year. 
Vaccination 
 Calves were vaccinated with a modified live vaccine (Bovi-Shield Gold 5, Zoetis). This 
vaccine contained antigens of 4 viruses that are associated with bovine respiratory disease: 
BVDV1, BVDV2, BRSV, and BHV1. Bovine parainfluenza 3 virus was also part of the 
modified live vaccine but was not included in this study. The vaccine was administered per 
manufacturers recommendation to the calves at 2 separate time points, designated initial 
vaccination (week 0) and booster vaccination (week 3). Calves were given the initial vaccine 
either at the time of weaning or 3 weeks prior, which resulted in weaning at booster vaccination. 
This was done to evaluate the effect of weaning as a stressor on response to vaccination. (Figure 
1). 
Dams of the calves studied received standard herd vaccinations during the course of this study. 
They received vaccinations approximately 40 days prior to breeding, and again at pregnancy 
check in the fall. These timings would have had negligible effects on circulating maternal 
antibodies for the calves studied. 
Serum sample collection 
 Serum samples were collected at 3 time points. The first sample was collected at initial 
vaccination (week 0), the second sample was collected at booster vaccination (week 3), and the 
third sample was collected 6 weeks after initial vaccination. Additionally, a subset of the total 
population used for this study had serum samples collected 3 weeks prior (week -3) to the initial 
vaccination (subset n = 622 for BVDV1, n = 1,137 for BVDV2). Blood was collected from the 
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jugular and allowed to coagulate overnight at 4 C. Tubes were centrifuged, after which serum 
was collected and separated into multiple 1.5 ml tubes and frozen at -20 C.  
Viral neutralization 
 Viral neutralization (VN) assays were performed to quantify the level of neutralizing 
antibodies present in serum against 4 viruses: BVDV1, BVDV2, BRSV, BHV1. Viral 
neutralization assays used the following virus strains, cytopathic BVDV1 strain Singer, 
cytopathic BVDV2 strain A125-C (both obtained from the National Animal Disease Center, 
USDA-ARS, Ames, IA) BRSV strain ATCC VR-794 and BHV1 strain Cooper (both obtained 
from National Veterinary Services Laboratory, Ames IA)(Fulton et al., 2000). Viral 
neutralization assays were performed as  previously described (Downey et al., 2013)(Bolin and 
Ridpath, 1990) with a few modifications between viruses. For BVDV1, 5 replicates were tested 
for each serum sample. For BVDV2, 5 replicates were tested for each serum sample for animals 
born before 2014, and 3 replicates were tested for individuals born in 2014. All serum samples 
were diluted 1:4 to 1:2048. For the BRSV and BHV1 assays 2 replicates were tested for each 
serum sample and serum samples were diluted between 1:8 and 1:2048. Two-fold dilutions of 
serum were done using phosphate-buffered saline. The titer was recorded for each calf as the log 
base 2 reciprocal of the greatest dilution at which neutralizing antibodies were detected. A cell 
control and viral control were run alongside BVDV1 and BVDV2. A cell control, positive serum 
control, and negative serum control were run for BRSV and BHV1. Antibody titer score was 
recorded as the average log base 2 reciprocal of the greatest dilution that neutralized virus across 
5 replicates. A modified calculation was done for samples with 3 replicates. An average log base 
2 reciprocal was taken across the 2 replicates for BHV1 and BRSV. If all wells within the first 
dilution showed a cytopathic effect, a titer score of 0 was given for the calf. Not all samples were 
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available for analysis for antibodies to each of the 4 viruses, which resulted in different subsets 
of individuals being tested for each virus.  
Response traits 
Seven antibody titer traits were analyzed. Maternal Antibody Titer Level at week -3 and 
Maternal Decay (MD; rate of change between week -3 and week 0) were only analyzed for 
BVDV1 (622 head) and BVDV2 (1137 head). Maternal antibody decay (MD) was defined as the 
difference between week -3 and week 0 divided by the difference in calf age between the 2 
serum collection dates (average calf age difference: 22 days for both BVDV1 and BVDV2). This 
was not exactly 21 days for each calf as all individuals in a single location had samples taken at 
the same time to minimize number of times interacting with the herd. 
Initial Antibody Titer Level was defined as the log base 2 antibody titer score observed at 
week zero. Initial Vaccination Response (IVR) was defined as the difference between antibody 
titer level observed at week 3 (booster vaccination time point) vs. week 0 (initial vaccination 
time point). Booster Vaccination Response (BVR) was defined as the difference in antibody titer 
level observed between week 6 (booster response time point) and week 3 (booster vaccination 
time point). Overall Vaccination Response (OVR) was defined as the difference in antibody titer 
level observed between week 6 (booster response time point) and week 0 (Initial vaccination 
time point). Final Antibody Titer Level was defined as the log base 2 antibody titer score 
observed at week 6 (Tait et al., 2013) (Fig. 1).  
Statistical analysis 
Environmental and systemic factors were evaluated to determine their potential effect on 
response to vaccination traits. Year-season classification were considered a single variable for 
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the purpose of this study, as previously described (Downey et al., 2013). Age within year-season 
was fit as a covariate. Additional contemporary group categories (date of serum batch analyzed, 
lab technician analyzing data, farm) were fit as covariates, but showed no statistical significance. 
 
Pre and initial antibody titer levels were analyzed using the following statistical model: 
ݕ௜௝௞௟௠ ൌ μ ൅ ܻ ௜ܵ ൅ ܦܣ௃ ൅ ܵ݁ݔ௞ ൅ ܫܦ௟ ൅ ܤ ௠ܹ ൅ ܣ௠ሺܻ ௜ܵሻ ൅ ݁௜௝௞௟௠ 
ܯ݋݈݀݁	1 
Where ݕ௜௝௞௟௠ was the pre or initial antibody titer for calf m. µ = overall mean, ܻ ௜ܵ = 
year-season classification [i = 2006 S, 2006 F, 2007 S, 2007 F, 2008 S, 2008 F, 2009 S, 2009 F, 
2010 S included for BVDV1, BRSV and BHV1. 2010 F included for BVDV1. 2011 S, 2011 F, 
2012 S, 2014 S but not 2006 S and 2006 F included for BVDV2], ܦܣ௃ = dam age [j = 2 to 11 
years of age. Ages 12 to 14 included for BVDV2], and ܵ݁ݔ௞ = calf sex (k = bull, steer, or heifer) 
were fit as fixed effects in the model. ܫܦ௟ = Dam ID for calf m, which was fit as a random effect 
to account for multiple progeny. ܤ ௠ܹ = Birth weight for calf m and ܣ௠ሺܻ ௜ܵሻ = calf age at pre or 
initial vaccination time point within year-season classification were fit as covariate effects. 
݁௜௝௞௟௠ = error term which was assumed to be normally distributed (mean = 0, variance = ߪଶ݁). 
Variables were removed from the model systematically until only variables with P < 0.05 
remained in the models. This resulted in a model with only significant factors and ܫܦ௟. 
 
Maternal antibody decay rate was analyzed using the following statistical model: 
ݕ௜௝௞௟௠ ൌ μ ൅ ܻ ௜ܵ ൅ ܦܣ௃ ൅ ܵ݁ݔ௞ ൅ ܫܦ௟ ൅ ܣ௠ሺܻ ௜ܵሻ ൅ ௠ܶ ൅ ݁௜௝௞௟௠ 
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ܯ݋݈݀݁	2 
Where ݕ௜௝௞௟௠ was the maternal antibody decay rate in titer level per day for calf m. µ 
=overall mean, ܻ ௜ܵ = year-season classification [i = 2006 S, 2006 F, 2007 S, 2007 F, 2008 S, 
2008 F, 2009 S, 2009 F, 2010 S included for BVDV1, BRSV and BHV1. 2010 F included for 
BVDV1. 2011 S, 2011 F, 2012 S, 2014 S but not 2006 S and 2006 F included for BVDV2], ܦܣ௃ 
= dam age [j = 2 to 11 years of age. Ages 12 to 14 included for BVDV2], and ܵ݁ݔ௞ = calf sex (k 
= bull, steer, or heifer) were fit as fixed effects in the model. ܫܦ௟ = Dam ID for calf m, which was 
fit as a random effect to account for multiple progeny. ܣ௠ሺܻ ௜ܵሻ = calf age at pre-vaccination 
within year-season classification and ௠ܶ = pre-vaccination antibody titer level for calf m were fit 
as covariate effects. ݁௜௝௞௟௠ = error term, which was assumed to be normally distributed (mean = 
0, variance = ߪଶ݁). Variables were removed from the model systematically until only variables 
with P < 0.05 remained in the model. This resulted in a model with only significant factors and 
ܫܦ௟. 
 
Response to vaccination traits (IVR, BVR, OVR, Final antibody titer) were analyzed using the 
following statistical model: 
ݕ௜௝௞௟௠௡௢ ൌ μ ൅ ܻ ௜ܵ ൅ ܵ݁ݔ௃ ൅ ௞ܹ ൅ ܲܧ௟ ൅ ܦܣ௠ ൅ ܫܦ௡ ൅ ௢ܶ ൅ ሺ ௢ܶݔ ௢ܶሻ ൅ ܣ௢ሺܻ ௜ܵሻ ൅ ܣܦܩ௢ ൅ ݁௜௝௞௟௠௡௢	 
ܯ݋݈݀݁	3 
Where ݕ௜௝௞௟௠௡௢ = IVR/BVR/OVR or final antibody level measured on calf o. ܻ ௜ܵ = year-
season classification [i = 2006 S, 2006 F, 2007 S, 2007 F, 2008 S, 2008 F, 2009 S, 2009 F, 2010 
S included for BVDV1, BRSV and BHV1. 2010 F included for BVDV1. 2011 S, 2011 F, 2012 
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S, 2014 S but not 2006 S and 2006 F included for BVDV2], ܵ݁ݔ௃ = calf sex (k = bull, steer, or 
heifer), ௞ܹ = weaning time (k = weaned at initial or booster vaccination), ܲܧ௟ = pinkeye 
classification at weaning (l = 0 for unaffected, 1 for affected), and ܦܣ௠ = dam age [j = 2 to 11 
years of age. Ages 12 to 14 included for BVDV2] were fit as fixed effects in the model.	ܫܦ௟ = 
Dam ID for calf m, which was fit as a random effect to account for multiple progeny. ௢ܶ = initial 
antibody level for calf o for IVR/OVR/final antibody level and booster antibody level for BVR, 
ሺ ௢ܶݔ ௢ܶሻ = quadratic effect for IVR/OVR/final antibody level and booster antibody level for 
BVR, ܣ௢ሺܻ ௜ܵሻ = calf age at vaccination (o = calf age at week 6 for final antibody level, age at 
initial vaccination for IVR and OVR, and age at week 3 for BVR) within year-season 
classification, and ܣܦܩ௢ = average daily gain for each of the 3 response variables (not fit for 
final antibody level) were fit as covariate effects. ݁௜௝௞௟௠௡௢ = error term which was assumed to be 
normally distributed (mean = 0, variance = ߪଶ݁). Variables were removed from the model 
systematically until only variables with P < 0.05 remained in the models. This resulted in a 
model with only significant factors and ܫܦ௟. 
Clustering 
Clustering of animals within a given virus category was done with SSClust3.0 (Ma et al., 
2006). The program was run with a chain number of 5, threshold of 0.1, and a cluster number of 
2+ for each population of individuals for each of the 4 viruses. Visual outputs from clustering 
analysis allowed for identification of subgroups of calve that responded differently to vaccination 
across the course of the study. 
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RESULTS 
The average age at initial vaccination was 138 days for BVDV1, 127 days for BVDV2, 
and 136 days for BHV1 and BRSV (SD = 31.3, 35.2, 29.6 in days). Average weight of calves at 
initial vaccination was 145.45 kg for BVDV1, 139.48 kg for BVDV2, and 150.51 kg for BRSV 
and BHV1 (SD = 5.1, 5.6, 5.1, respectively). Average age and weight of calves varied among the 
different antigens due to differences in the number of individuals with recorded serum titers for 
each antigen, which resulted in different total numbers of calves for each antigen group. The 
proportion of male calves to female calves was relatively equal, with males being slightly more 
common (males = 864 for BVDV1, 1191 for BVDV2, and 849 for BRSV and BHV1; females = 
791 for BVDV1, 1041 for BVDV2, and 783 for BRSV and BHV1). Table 1 shows the number of 
animals tested for antibodies against each virus per time point, as well as the mean, standard 
deviations and range for antibody titer, body weight, and age at each time point. 
 Pre-vaccination and initial vaccination antibody titers were affected by Year-season, Dam 
age, Birth weight, and Age within year-season (Table 2). Dam age was positively correlated with 
increased initial titer levels for all viruses with the exception of BHV1 (Fig. 2). For BVDV1, 
maternal antibody titer increased as dam age increased up to 8 years of age. The spike in 
maternal antibody titer was likely due to the large standard error that resulted from low numbers 
of representative dams at this age. BVDV2, BRSV and BHV1 titer levels increased as dam age 
increase up to 7 years of age. Initial antibody titers decreased (P < 0.05) as calf age increased 
although at varying rates between the 4 viruses (Fig. 3). 
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Maternal decay 
 Maternal antibody decay rate was evaluated for BVDV1 and BVDV2. No pre-
vaccination data was collected for BRSV or BHV1, so the rate of decay of serum antibody 
before the first vaccination could not be determined. Year-season classification, Dam age, Sex, 
Age within year-season classification, and Pre-vaccination levels significantly affected the decay 
rate of BVDV2 maternal antibody level. For BVDV1 only Dam age, Age within year-season, 
and Pre-vaccination levels were significant (Table 2). The rate of decay of BVDV1 maternal 
antibody level generally decreased as dam age increased. In contrast, the rate of decay of 
BVDV2 maternal antibody level remained relatively constant across dam age (Table 3). Calf age 
was inversely correlated with rate of decay for both BVDV1 and BVDV2, with older calves 
having a greater rate of decay than younger calves (Fig. 4). For BVDV1 and BVDV2, pre-
vaccination maternal antibody titers were inversely correlated with rate of decay. A 1 unit 
increase in prevaccination maternal antibody titer corresponded to a 0.01698 titer units/day 
decrease in maternal antibody decay rate for BVDV1 and 0.01139 titer units/day for BVDV2 (P 
< 0.0001). 
Response to vaccination 
Response to vaccination may be influenced by factors other than circulating maternal 
antibodies. Thus, other environmental factors were evaluated for their effect on initial response 
to vaccination, booster response to vaccination, overall response to vaccination, and final 
antibody titer. All factors in Model 3 were tested, and results can be found in Table 4. Sex was 
only significant for initial vaccination titer for BRSV. Average daily gain of the calf was only 
significantly associated with the initial response of BVDV1 vaccination. The observed baseline 
titer, i.e. the antibody titer at the first time point used to calculate a vaccination trait (e.g. the titer 
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at week 0 for IVR, OVR, and Final Antibody titer, or the week 3 antibody titer for BVR) was 
significant for every trait with the exception of the final antibody titer for BRSV and the IVR for 
BVDV1. Age within year-season classification was significant for all traits. Weaning date was 
significant for many traits, and individuals were classified as either weaned at week 0 or week 3. 
Weaning classification was associated with increased overall antibody response to BVDV1 and 
BVDV2 when calves were weaned at initial vaccination. Weaning classification was also 
associated with increased OVR in BRSV and BHV1 when calves were weaned at booster 
vaccination (see for example results for calves receiving initial vaccination at weaning and 
having a dam aged 5 years old, in Fig. 5).  Pink eye occurrence was statistically significant for 
only a few time points across all 4 viruses (BVDV1 Final titer level; BVDV2 IVR, OVR, Final 
titer level; BHV1 IVR). 
The effect of calf age at first vaccination within year-season classification was averaged 
across all year-seasons for a given virus and time point, and compared between the 4 viruses. 
This was done to help account for birthing conditions that can vary considerably between spring 
and late summer/early fall in the Midwest United States. For initial vaccination response, an 
increase in calf age resulted in a lower IVR for all viruses with the exception of BVDV1, which 
increased slightly as calf age increased (Fig. 6a). Booster vaccination response increased with 
calf age for all 4 viruses (Fig. 6b). Overall vaccination response increased with calf age for all 
viruses, with the exception of BRSV, which resulted in a slight decrease in OVR with increased 
age (Fig. 6c). Final titer increased with calf age for BVDV1 and BVDV2, yet decreased with age 
in BRSV and BHV1 (Fig. 6d). Supplemental Figures 1 to 4 show the aforementioned trends 
when not averaged across year-seasons. 
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The observed baseline titer, i.e. the antibody titer at the start of a response to vaccination 
trait (e.g. titer score at week 0 for IVR, OVR, and final antibody titer, or week 3 antibody titer 
for BVR) was also averaged across all year-season classifications and compared between the 4 
viruses (Fig. 7). Supplemental Figures 5 to 8 show the same trends but not averaged across year-
season. For all 4 response to vaccination traits (IVR, BVR, OVR and final antibody titer level) 
antibody titer decreased as their respective baseline titer increased. To have a positive initial 
vaccination response, initial antibody level (week 0) needed to be below 1.5 for BVDV2 and 
BHV1, but below 0.38 for BVDV1 and 3.88 for BRSV (Fig. 7a). To have a positive booster 
vaccination response, the week 3 antibody level needed to be below 1.73 for BVDV1, 3.32 for 
BVDV2, 4.50 for BRSV and 2.38 for BHV1 (Fig. 7b). To have a positive overall vaccination 
response, week 0 antibody level needed to be below 1.55 for BVDV1, 2.71 for BVDV2, 4.12 for 
BRSV and 1.29 for BHV1 (Fig. 7c). Final antibody titer decreased for all viruses as week 0 
antibody concentration increased. BRSV also saw a decrease in final antibody titer as week 0 
antibody concentration increased, but at a slow decline compared to the other 3 viruses, with a 
theoretical final antibody titer score of zero only when initial antibody levels are at 184.92 titer 
units (Fig. 7d). Figures 6 and 7 show trends for calves aged 55 to 200 days of age, although the 
true age range for each virus at each time point can be seen in Table 1.  
The overall antibody titer level trend was plotted for each virus across the 3 (or 4) serum 
collection time points (Fig. 8). The overall trend was fit utilizing model 1, and all non-significant 
factors were removed before being fit. Each time point had age within year-season classification 
fit as the average age of calves with records. For BVDV1 and BVDV2, sex and birth-weight 
were included in the final model, while for BRSV and BHV1 they were not significant. Titers to 
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BVDV1 and BVDV2 were observed to decrease from week -3 to week 3, and then increase from 
week 3 to week 6. Titers to BRSV and BHV1 increased from week 0 to week 6.  
Titer curves for each virus across all individuals are shown in Fig. 9. Average titer across 
time is plotted as green lines, while individuals were plotted as grey lines. Fig. 10 shows the titer 
curves for individual animals that had a titer of 0 for BVDV1, BVDV2, and BHV1 at week 6. 
BRSV was included for the sake of comparison by plotting only individuals with a final titer 
level of 3, as no individual failed to seroconvert for BRSV at week 6. There were 367, 100 and 
468 calves that had a titer of 0 at week 6 against BVDV1, BVDV2 and BHV1, respectively.  
Of the 367 individuals that had a final titer of 0 for BVDV1, 107 of these calves had a 
titer of 0 at all time points, 119 calves did not obtain a titer of 0 until week 6, 96 calves had a 
titer of 0 by week 3, 19 calves obtained and maintained a titer of 0 by week 0 (required pre-
vaccination data), while 26 calves exhibited titers that oscillated or had missing data at weeks 0 
or 3. Of the 100 individuals that had a final titer of 0 for BVDV2, 9 of these calves had a titer of 
0 at all time points, 57 calves did not obtain a titer of 0 until week 6, 27 calves had a titer of 0 by 
week 3, 3 calves obtained and maintained a titer of 0 by week 0 (required pre-vaccination data), 
while 4 calves exhibited titers that oscillated or had missing data at weeks 0 or 3. Of the 468 
individuals that had a final titer of 0 for BHV1, 227 of these calves had a titer of 0 at all time 
points, 62 caves did not obtain a titer of 0 until week 6, 70 calves had a titer of 0 by week 3, 109 
calves obtained and maintained a titer of 0 by week 0 (required pre-vaccination data), while 109 
exhibited titers that oscillated or had missing data at weeks 0 or 3. Oscillating titers for these 
plots was defined as a titer change from positive/0/positive, or from 0/positive/0 at some point 
across all measurement time points. 132 individuals for BRSV were shown who had a final titer 
of 3 (the lowest recorded titer score at week 6). 
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Titer trends for each virus were plotted across time with SSClust3.0 (Ma et al., 2006). 
The mean curve for each cluster was obtained and plotted as a black line, alongside a 95% 
confidence interval in red. Curves for the four clusters within BVDV1 can be seen in Fig. 11. 
Interpolation between time points can be seen between each of the 4 time points (pre-vaccination 
[-3], initial vaccination [0], booster vaccination [3], and booster response [6]). The y-axis 
represents proportional titer level compared to a base level of 1 determined by SSClust3.0 for 
each cluster. Additional trends for the other 3 viruses can be found in supplemental Figures 9 to 
11. 
DISCUSSION 
An individual’s titer can be indicative of immunological health, and therefore may be 
useful for determining which individuals are more responsive to vaccination protocols and thus 
better contributors to herd immunity in livestock (Sharma et al., 2016). By utilizing 4 viruses 
commonly associated with BRDC, we showed that there are various factors that impact response 
to vaccination in pre-feedlot calves, and that these factors may not be the same for all viruses. 
While we only measured responses to all 4 viruses from 1,273 calves, for some viruses we report 
results for more calves when they were available. The inclusion of additional data from more 
calves did not significantly alter observed results.  
Maternally-derived antibodies serve an important purpose in protection for calves during 
their early developmental lifetime, but the suppressive effects of maternal antibodies on 
vaccination may hamper the ability to determine the calf’s own immunological response for an 
individual as measured by seroconversion (Fulton et al., 2004; Guzman and Taylor, 2015). 
Maternal antibody decay was examined for both BVDV1 and BVDV2 by determining the rate of 
decay in antibody titer from 3 weeks before initial vaccination to the initial vaccination at week 
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0. The rate of decay for BVDV2 titers were always greater than for BVDV1 titers at a given calf 
age, although the change in rate of decay as calves aged was greater for BVDV1 than for 
BVDV2. The greater rate of decay of BVDV2 was likely due to greater average maternal 
antibody titer levels compared to BVDV1 (O'Neill et al., 2006). It may also be due in part to 
fewer calves (622) with pre-vaccination data for BVDV1 than the number with prevaccination 
data for BVDV2 (1137), however this is purely speculative in nature. The rate of maternal 
antibody decay increased with calf age, which was consistent with other studies on maternal 
circulating antibodies (Kirkpatrick et al., 2008), and followed closely with a previous work 
examining maternal decay and BVDV2 titers (Downey et al., 2013). Rates of decay for both 
BVDV1 and BVDV2 indicated that by initial vaccination at week 0, many individuals had low 
enough circulating maternally-derived antibodies to mount a resonse to vaccination. The level of 
circulating maternally-derived antibody was directly related to calf and dam age. Higher 
birthweights were found to be significantly associated with higher maternally-derived antibody 
levels at initial vaccination, although their actual effect was minor compared to other factors. All 
discussion on observed response to vaccination must be tempered with the knowledge that 
circulating maternally-derived antibodies may still have been binding to antigens. Therefore, the 
observed responses may have been different if calves had no maternal antibodies at the time of 
vaccination.  
Weaning has been associated with increased stress in calves, and stress has been 
implicated in negatively affecting the immune response of individuals (Hulbert and Moisa, 
2016). To determine the effect of weaning stress, approximately half of the calves used for this 
study were weaned at initial vaccination (week 0) with the other half weaned at booster 
vaccination (week 3). Results indicate that titers to BVDV1 and BVDV2 increased significantly 
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more when calves received their initial vaccination at the time of weaning; in contrast, titers to 
BHV1 and BRSV increased significantly more when calves received their initial vaccination 3 
weeks before weaning. However, it is important to remember that titers for different calves were 
included in the model describing the responses to BVDV1/BVDV2, and BHV1/BRSV. Thus it 
may not be valid to make a comparison between the responses to BVDV1/BVDV2 and 
BRSV/BHV1. The same calves were included in the models describing BRSV and BHV1, so 
comparison between the responses to those viruses may be more appropriate. 
A decrease in initial antibody titer score for BVDV1 and BVDV2 was likely linked to 
greater baseline titer values, i.e. the antibody titer score at week 0, compared to BRSV and 
BHV1. Increased calf age was associated with greater overall vaccination response for all viruses 
with the exception of BRSV (rate of titer score increase as calf age increased was different for 
BVDV1, BVDV2 and BHV1). This was in agreement with a previous study which focused 
solely on BVDV2 (Downey et al., 2013). The decrease in initial antibody titer is understandable 
as the lower maternal antibodies found in older individuals would allow for the immune system 
to respond with increased antibody production to the presence of viruses (Munoz-Zanzi et al., 
2002). For an antibody response to be mounted in the presence of viral antigens, it appears that 
an individual’s circulated antibodies to that antigen must be below a specific threshold. If 
circulating antibodies are above this threshold, they may bind the viral antigens while reducing 
stimulation of the individual’s immune system, as seen by decreasing titer levels for individuals 
with high initial vaccination titers. Changes in trends for each response variable as base titer 
level increased (e.g. titer score at week 0 for IVR, OVR, and Final antibody level or week 3 
antibody titer level for BVR) were obtained to assist in identifying antibody response in relation 
to a respective antibody level at a given time. The intersection of the trend line with x-axis 
  19
indicates an observed titer level at which an individual would positively respond to the presence 
of the virus if circulating antibodies were below the x-value of the intersection, or fail to respond 
if circulating antibodies were above that value. For BVDV1 and BVDV2, the threshold was 0.38 
and 1.5 log-base 2 titer, which explains the initial titer score decrease from week 0 to week 3 
observed in BVDV1 and BVDV2.  
The BRSV titer values remained relatively constant across calf age for all response 
variables, indicating that there would be a response at any calf age. While it was not possible to 
confirm an exact reason for this behavior, it may be due to the ubiquitous nature of BRSV in the 
environment (Ellis et al., 2005). This would indicate that most calves had already been exposed 
to BRSV at some point in their early life, and as such already have the ability to generate 
antibodies in the presence of the BRSV antigen. This indicated that calves, on average, were 
always able to respond to the presence of BRSV antigens and that vaccination may not be 
responsible for these observations. 
This ubiquitous nature of BRSV may also explain why every calf seroconverted by week 
6 for BRSV. The lowest recorded final antibody titer for BRSV was 3 on the log base-2 scale, 
while BVDV1, BDVD2, and BHV1 all had some proportion of individuals with a final antibody 
titer of 0. The minimum possible record above 0 does differ between the four viruses, as BRSV 
and BHV1 had only 2 assay replicates done per viral neutralization dilution compared to the 3 or 
5 assay replicates for BVDV1 and BVDV2. This would only allow BRSV and BHV1 to have 
final titers between 1.7 and 3 at a minimum, however it would not prevent final titers of 0 as seen 
in BHV1 observations. Again, the likely presence of BRSV throughout the herd is the most 
probable cause for why some animals did not seroconvert for the other 3 viruses but every 
individual measured for antibody response to BRSV managed to seroconvert.  
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A large amount of variation was found to be present in vaccine responses between 
individuals, leading to the question of if there were clusters of individuals who exhibited similar 
responses to vaccination. Average titer trends and the 95% confidence interval for each virus was 
plotted with SSClust3.0, which identified subsets of individuals (clusters) who exhibited similar 
responses to selection. These clusters may indicate differences of within herd antibody 
production or immune system strength, as some clusters appeared to respond less robustly than 
others. 
For the proportion of individuals who did not seroconvert by week 6 to BVDV1, 
BVDV2, and BHV1, there are individuals who never seroconvert at any time point, and those 
who had recorded antibody titers that dropped to 0 at some time period after the first 
measurement. The most interesting individuals are those that never seroconvert despite having 
maternal antibodies and 2 rounds of vaccination. There were 107 individuals who never 
seroconverted to BVDV1, 9 individuals that never seroconverted to BVDV2, and 227 individuals 
that never seroconverted to BHV1. This is 6.5%, 0.4%, and 13.9% of the respective set of 
animals with records for the given virus studied who failed to seroconvert. One calf failed to 
seroconvert for both BVDV1 and BVDV2, and 12 calves failed to seroconvert for both BVDV1 
and BHV1. There were no calves that failed to seroconvert for both BVDV2 and BHV1, and 
consequently no calves that failed to seroconvert for all 3 viruses. Growth traits did not 
significantly differ between animals who seroconverted and those who did not, indicating that 
development of the calves was not hindered by a lack of immune response up to the point at 
which serum samples were collected. Although individuals who did not seroconvert still grew 
normally and may be protected in herds due to herd immunity, these would be the most at risk 
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individuals and therefore likely the ones to be culled so as to potentially reduce morbidity 
incidence in the herd. 
To address methodology, a reduction in assay replicates occurred in later years of 
BVDV2 (5 to 3 replicates). Additionally, BHV1 along with BRSV were analyzed with only 2 
replicates as opposed to 5. While reduction in assay replicates is likely to reduce overall accuracy 
of recorded measurements, this was done to improve statistical power by increasing the number 
of individuals with measured serum levels. By improving our power to statistically analyze 
observed measurements, we are able to better estimate trends in the population. This does lower 
the ability to analyze individuals on a one-by-one basis, however this is not the goal of this 
particular study. 
  In summary, an individual’s response to vaccination was influenced by multiple 
factors, including initial maternally-derived circulating antibodies, time of weaning, and age of 
the calf. When these factors are considered together, it indicates that calves have on average a 
more positive response to vaccination when they are older, likely due to a reduced quantity of 
circulating maternally-derived antibodies. Time of weaning relative to initial vaccination 
impacted overall response to vaccination for a given virus. Individuals with recorded BVDV1 
and BVDV2 titers had more robust overall antibody responses when initially vaccinated at the 
time of weaning, while individuals with recorded BRSV and BHV1 titers had more robust 
overall antibody response to vaccination when weaned 3 weeks after that initial vaccination. This 
difference in robustness of response to vacciantion indicates that the stress associated with 
weaning impacts response to vaccination differently for different viruses. It is still important to 
note that not all individuals had titers recorded for all 4 viruses, and therefore direct response 
comparisons cannot be made for every individual and can only be made based on overall herd 
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averages. A proportion of the calf population was identified as non-responders or individuals 
who failed to seroconvert at week 6. No reduced growth or development was associated with that 
proportion of individuals at the time of serum collection, possibly due to the effect of herd 
immunity. Genomic analysis of these individuals will be important, however, due to their 
potentially weaker genetics in respect to antibody production. All of this together helps develop a 
more beneficial direction under which vaccinations could be administered.  
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Figure Captions: 
Figure 1: Timeline of serum sample collection. Pre-vaccination time point (-3 weeks) samples 
were only tested for BVDV1 and BVDV2. 
Figure 2: Average initial antibody concentration by dam age in years for A) BVDV1, B) 
BVDV2, C) BRSV and D) BHV1. Pre-vaccination titers by dam age included for BVDV1 and 
BVDV2. Different letters indicate significantly different dam ages at P < 0.05. 
Figure 3: Initial antibody titer (week 0) by calf age in days, averaged across year-season 
classification for BVDV1, BVDV2, BRSV and BHV1 and extrapolated between 50 and 200 
days of age. 
Figure 4: Weighted Average of Maternal antibody decay rate (titer unit/day) by prevaccination 
age of calf for BVDV1 and BVDV2 and extrapolated between 50 and 200 days of age. 
Figure 5: Change in average overall antibody response by weaning time point for BVDV1, 
BVDV2, BRSV and BHV1. Significant differences between weaning classification represented 
with different letters above error bars. 
Figure 6: Estimated response traits and final antibody titer by calf age in days for BVDV1 (n 
=1654), BVDV2 (n = 2231), BRSV (n=1631), BHV1 (n=1631). A) Initial vaccination response, 
B) Booster vaccination response, C) Overall vaccination Response, D) Final Antibody Titer. 
Covariates of weaning at initial vaccination, Pink Eye = yes, dam age = 5 years. Slope indicates 
weighted average effect of age; vertical shift indicates weighted average year-season effect. 
Figure 7: Response traits and final antibody titer normalized by starting titer for BVDV1 (n 
=1654), BVDV2 (n = 2231), BRSV (n=1631), BHV1 (n=1631). A) Initial vaccination response, 
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B) Booster vaccination response, C) Overall vaccination Response, D) Final Antibody Titer. 
Covariates of weaning at initial vaccination, Pink Eye = yes, dam age = 5 years. Slope indicates 
weighted average effect of base titer; vertical shift indicates weighted average year-season effect. 
Figure 8: Average titer over time for each of four viruses. Trend fit using model 1 and removing 
any non-significant factors. 
Figure 9: Titers across serum collection time points. A) BVDV1 (n =1654), B) BVDV2 (n = 
2231), C) BRSV (n=1631), D) BHV1 (n=1631). Average titer level plotted in green, all 
individuals plotted in grey.  
Figure 10: Individuals with a final titer of zero. A) BVDV1 (n = 367), B) BVDV2 (n = 100), C) 
BHV1 (n = 468). Average titer level across all individuals measured is plotted in green. D) 
BRSV (n = 132) shows individuals with the minimum titer calculated at week six (3 on a log 
base-2 scale). While it is not the same trend as shown in A, B and C, it was included to allow 
comparison.  
Figure 11: Trends within individuals with measured BVDV1 data. Four clusters were generated, 
with n = 163 calves for cluster 1, n = 524 calves for cluster 2, n = 136 calves for cluster 3, and n 
= 809 calves for cluster 4. X-axis shows titer measurement time points (pre-vaccination, initial 
vaccination, booster vaccination, and booster response). Y-axis represents average titer of 
cluster, calculated proportional to other time points, with a score of 1 being the reference. Black 
lines represent mean titer trends; red lines represent 95% confidence interval. 
  25
Table 1: Means for titer, calf age, and calf weight at four time points for Bovine Viral Diarrhea Virus 1 (BVDV1), Bovine Viral 
Diarrhea Virus 2 (BVDV2), Bovine Respiratory Syncytial Virus (BRSV), and Bovine Herpesvirus 1 (BHV1) 
BVDV1 
Calf 
Number  Titer, log base‐2 Range SD Age, days  SD  Range BW, kg SD
Pre‐vaccination1  622  2.68 (0‐12.3) 2.68 111.8  27.9 (28‐169) 133.4 30.6
Initial Vaccination  1,648  2.14 (0‐10.5) 2.15 138.0  29.4 (54‐205) 149.2 34.5
Booster Vaccination  1,488  1.5 (0‐9.3) 1.7 158.6  29.7 (76‐229) 173.8 39.7
Final   1,348  2.3 (0‐9.3) 1.8 177.9  29.1 (99‐250) 190.1 40.0
Decay, titer/day2  622  ‐0.023   0.06           
BVDV2 
Pre‐vaccination1  1,137  4 (0‐10.5) 2.32 109.1  28.7 (28‐165) 145.3 34.1
Initial Vaccination  2,177  3.24 (0‐11.2) 2.38 127.0  35.0 (30‐205) 143.2 37.5
Booster Vaccination  1,927  2.5 (0‐11.3) 1.98 152.9  31.4 (57‐229) 164.3 39.7
Final   1,917  4.17 (0‐9.16) 1.91 174.9  30.9 (78‐250) 182.3 42.6
Decay, titer/day2  1,137  ‐0.041   0.045           
BRSV 
Initial Vaccination  1,632  1.08 (0‐6) 1.81 136.3  29.6 (53‐205) 150.5 36.1
Booster Vaccination  1,310  3.73 (3‐6) 0.81 151.1  28.0 (76‐229) 170.9 39.1
Final   1,483  5 (3‐6.46) 0.89 177.3  35.0 (99‐250) 189.5 40.3
BHV1 
Initial Vaccination  1,621  0.87 (0‐6) 1.45 136.3  29.6 (53‐205) 150.3 36.1
Booster Vaccination  1,351  2.1 (0‐6) 1.79 156.8  29.7 (76‐229) 170.4 38.9
Final   1,377  2.98 (0‐6.58) 2.3 177.5  34.0 (99‐250) 189.6 40.2
1Viral Neutralization titers to BRSV and BHV1 were not measured in pre-vaccination samples thus results for pre-vaccination and decay are only 
reported for BVDV1 and BVDV2.  
2Titer reported as titer/day change for Maternal Decay.
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Table 2: Significance for fixed effects relating to initial antibody titer, pre-vaccination antibody 
titer, and maternal decay for Bovine Viral Diarrhea Virus 1 (BVDV1) and Bovine Viral Diarrhea 
Virus 2 (BVDV2)1 
BVDV1  Initial  Pre‐vaccination Decay
Year‐Season  <0.0001  0.0012 0.471
Dam Age  <0.0001  <0.0001 0.0012
Sex  0.2431  0.2201 0.9292
Birth Weight  0.0006  0.0012 *****
Age(Year‐Season)  <0.0001  <0.0001 0.2002
Pre‐vaccination level  *****  ***** <0.0001
BVDV2  Initial  Pre‐vaccination Decay
Year‐Season  <0.0001  0.004 <0.0001
Dam Age  <0.0001  <0.0001 0.0012
Sex  0.099  0.3292 0.1383
Birth Weight  <0.0001  0.0136 *****
Age(Year‐Season)  <0.0001  <0.0001 <0.0001
Pre‐vaccination level  *****  ***** <0.0001
1Viral Neutralization titers to BRSV and BHV1 were not measured in pre-vaccination samples, thus 
results are only reported for BVDV1 and BVDV2. 
*****: Variable not tested.
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Table 3: Rate of maternal antibody decay by dam age for Bovine Viral Diarrhea Virus 1 (BVDV1) and Bovine Viral Diarrhea Virus 2 
(BVDV2) 
BVDV1  Dam Age  Rate of Decay  Standard Error BVDV2 Dam Age  Rate of Decay Standard Error
   2a  ‐0.01911  ±0.008584   2a  ‐0.06558 ±0.004561
3b  ‐0.04109  ±0.007251 3b  ‐0.05428 ±0.003819
4b  ‐0.03863  ±0.007018 4b  ‐0.04727 ±0.003845
5ab  ‐0.0339  ±0.009137 5b  ‐0.05251 ±0.004357
6a  ‐0.00956  ±0.009723 6bc  ‐0.04466 ±0.00471
7a  ‐0.00958  ±0.009905 7cd  ‐0.03717 ±0.00474
8a  ‐0.00292  ±0.01236 8bde  ‐0.0435 ±0.005412
9a  ‐0.00307  ±0.01422 9ab  ‐0.04938 ±0.005677
10ac  0.0232  ±0.02755 10ab  ‐0.05465 ±0.008574
11c  0.06686  ±0.03497 11ce  ‐0.02878 ±0.00935
12abc  ‐0.05348 ±0.02315
13abc  ‐0.0683 ±0.03974
               14abc  ‐0.0554 ±0.03959
a-e: Different superscripts indicate significantly different estimates at P < 0.05 within a single virus analyzed. 
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Table 4: Class effects and covariates associated with initial response, booster response, overall response, and final antibody titer for 
Bovine Viral Diarrhea Virus 1 (BVDV1), Bovine Viral Diarrhea Virus 2 (BVDV2), Bovine Respiratory Syncytial Virus (BRSV), and 
Bovine Herpesvirus 1 (BHV1) 
BVDV1  Initial Response Booster Response Overall Response  Final Antibody Level
Year‐season  0.05 0.0823 0.0047  <0.0001
Sex  0.3856 0.904 0.984  0.9507
Pink Eye  0.6824 0.2001 0.116  0.013
Dam Age  0.0034 0.0256 0.0024  0.029
Wean  0.2726 0.0526 0.0004  0.0022
Titer  0.2605 <0.0001 <0.0001  <0.0001
Titer*Titer  <0.0001 <0.0001 <0.0001  <0.0001
Age(Year‐season)  <0.0001 <0.0001 0.0003  <0.0001
ADG  0.0015 0.7861 0.7427  *****
BVDV2  Initial Response Booster Response Overall Response  Final Antibody Level
Year‐season  0.0007 <0.0001 <0.0001  <0.0001
Sex  0.8879 0.0573 0.2283  0.2379
Pink Eye  0.0055 0.2236 0.0195  0.0181
Dam Age  0.0518 <0.0001 <0.0001  <0.0001
Wean  <0.0001 0.0746 0.0012  0.0005
Titer  <0.0001 <0.0001 <0.0001  <0.0001
Titer*Titer  <0.0001 <0.0001 <0.0001  <0.0001
Age(Year‐season)  <0.0001 <0.0001 <0.0001  <0.0001
ADG  0.3792 0.3478 0.1834  *****
BRSV  Initial Response Booster Response Overall Response  Final Antibody Level
Year‐season  <0.0001 <0.0001 <0.0001  <0.0001
Sex  0.0311 0.1712 0.2633  0.2362
Pink Eye  0.1375 0.5948 0.766  0.9354
Dam Age  0.6456 0.04 0.0002  <0.0001
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Wean  0.5632 <0.0001 <0.0001  <0.0001
Titer  <0.0001 <0.0001 <0.0001  0.4414
Titer*Titer  0.931 0.585 0.1151  0.124
Age(Year‐season)  <0.0001 <0.0001 <0.0001  <0.0001
ADG  0.9364 0.1578 0.958  *****
BHV1  Initial Response Booster Response Overall Response  Final Antibody Level
Year‐season  <0.0001 <0.0001 <0.0001  <0.0001
Sex  0.0751 0.7596 0.4038  0.4557
Pink Eye  0.0128 0.6701 0.6821  0.7563
Dam Age  <0.0001 0.0352 0.0021  0.0002
Wean  0.0004 <0.0001 <0.0001  <0.0001
Titer  <0.0001 <0.0001 <0.0001  <0.0001
Titer*Titer  0.7269 0.8379 <0.0001  <0.0001
Age(Year‐season)  <0.0001 <0.0001 <0.0001  <0.0001
ADG  0.3721 0.387 0.2336  *****
 
*****: Not tested for column trait.
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Figure 4: 
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Figure 5: 
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Figure 7: 
‐10 
‐8 
‐6 
‐4 
‐2 
0 
2 
4 
6 
0
 
0
.
5
 
1
 
1
.
5
 
2
 
2
.
5
 
3
 
3
.
5
 
4
 
4
.
5
 
5
 
5
.
5
 
6
 
6
.
5
 
7
 
7
.
5
 
8
 
8
.
5
 
9
 
9
.
5
 
1
0
 
I
n
i
a
l
 
V
a
c
c
i
n
a
o
n
 
R
e
s
p
o
n
s
e
,
 
b
a
s
e
 
2
 
l
o
g
 
Ini al An body Titer, base 2 log 
A 
BVDV1 
BVDV2 
BRSV 
BHV1 
‐8 
‐6 
‐4 
‐2 
0 
2 
4 
6 
0
 
0
.
5
 
1
 
1
.
5
 
2
 
2
.
5
 
3
 
3
.
5
 
4
 
4
.
5
 
5
 
5
.
5
 
6
 
6
.
5
 
7
 
7
.
5
 
8
 
8
.
5
 
9
 
9
.
5
 
1
0
 
B
o
o
s
t
e
r
 
V
a
c
c
i
n
a
o
n
 
R
e
s
p
o
n
s
e
,
 
b
a
s
e
 
2
 
l
o
g
 
Booster An body Titer, base 2 log 
B BVDV1 BVDV2 
BRSV 
BHV1 
‐14 
‐12 
‐10 
‐8 
‐6 
‐4 
‐2 
0 
2 
4 
6 
0
 
0
.
5
 
1
 
1
.
5
 
2
 
2
.
5
 
3
 
3
.
5
 
4
 
4
.
5
 
5
 
5
.
5
 
6
 
6
.
5
 
7
 
7
.
5
 
8
 
8
.
5
 
9
 
9
.
5
 
1
0
 
O
v
e
r
a
l
l
 
V
a
c
c
i
n
a
o
n
 
R
e
s
p
o
n
s
e
,
 
b
a
s
e
 
2
 
l
o
g
 
Ini al An body Titerlevel, base 2 log 
C 
BVDV1 
BVDV2 
BRSV 
BHV1 
‐4 
‐3 
‐2 
‐1 
0 
1 
2 
3 
4 
5 
6 
0
 
0
.
5
 
1
 
1
.
5
 
2
 
2
.
5
 
3
 
3
.
5
 
4
 
4
.
5
 
5
 
5
.
5
 
6
 
6
.
5
 
7
 
7
.
5
 
8
 
8
.
5
 
9
 
9
.
5
 
1
0
 
F
i
n
a
l
 
A
n
b
o
d
y
 
T
i
t
e
r
,
 
b
a
s
e
 
2
 
l
o
g
 
Ini al An body Titerlevel, base 2 log 
D 
BVDV1 
BVDV2 
BRSV 
BHV1 
  37
Figure 8: 
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Figure 9: 
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Figure 10: 
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